More potent ESR1 antagonists, such as AZD9496, have recently been reported to be more effective than fulvestrant (even used at supra-clinical doses) or tamoxifen in pre-clinical ESR1 mutant breast tumour models [21]. This evidence concerns the gene ESR1 and breast neoplasm.